EXPERIMENTAL RATIONALE FOR THE USE OF ROPRENE TO PREVENT ISONIAZID-INDUCED LIVER DAMAGES

Abstract

A model of isoniazid-induced liver damage in fast (females) and slow (males) acetylators was used to study the preventive hepatoprotective effect of the novel drug roprene in doses of 10, 15, and 30 mg/kg as an oil solution. It was found that in terms of a set of biochemical and morphological criteria, the most marked hepatoprotective effect of roprene given in a dose of 10 mg/kg and particularly 30 mg/kg was seen in the fast acetylators. In terms of morphological criteria for assessment, the most pronounced hepatoprotective effect of roprene used in a dose of 10 mg/kg and especially 30 mg/kg was observed in the slow acetylators. According to biochemical parameters, there was no advantage of any of the used doses (10, 15, and 30 mg/kg) of roprene in their effect on altered parameters. There is experimental evidence that it is advisable to use roprene to prevent isoniazid-induced hepatotoxicity in the patients with tuberculosis, primarily in the fast acetylators.